BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Ascletis, CR Pharma sign strategic cooperation agreement

June 27, 2018 | News

The two parties will work closely in distribution networks and end-user services, to prepare for the launch of Ganovo.

Ascletis BioScience Co., Ltd. and CR Pharmaceutical Commercial Group Co., Ltd. have jointly announced that the two parties signed a strategic cooperation agreement in Beijing. The two parties will work closely in distribution networks and end-user services, to prepare for the launch of Ganovo (danoprevir).

Ganovo, Ascletis' first innovative drug and the first direct-acting anti-viral agent developed by a domestic company in China, was approved by the China Food and Drug Administration on June 8, 2018. In the phase III clinical trial conducted in Mainland China, Ganovo regimen (Ganovo in combination with pegylated interferon and ribavirin) demonstrated a cure rate of 97% (SVR12) in genotype 1 non-cirrhotic patients, in a 12-week treatment duration.

CR Pharmaceutical Commercial Group Co., Ltd., a subsidiary and grade-1 profit center of China Resources Pharmaceutical Group Limited (CR Pharma), is the second largest distributor in Chinese pharmaceutical market for sales and distribution services including marketing & sales, distribution and logistics, academic seminars and supply chain value added services. CR Pharmaceutical Commercial Group Co., Ltd. directly distributes products to hospitals and other medical institutions in 31 provinces in China.